Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China. The company offers traditional Chinese medicine and chemical medicine. It also focuses on the fields of cardiovascular, respiratory, ophthalmology, and digestive. Guangdong Zhongsheng Pharmaceutical Co., Ltd. was founded in 1979 and is based in Dongguan, China.
Guangdong Zhongsheng Pharmaceutical Co Ltd (002317) - Total Assets
Latest total assets as of September 2025: CN¥5.17 Billion CNY
Based on the latest financial reports, Guangdong Zhongsheng Pharmaceutical Co Ltd (002317) holds total assets worth CN¥5.17 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Guangdong Zhongsheng Pharmaceutical Co Ltd - Total Assets Trend (2006–2024)
This chart illustrates how Guangdong Zhongsheng Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Guangdong Zhongsheng Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Guangdong Zhongsheng Pharmaceutical Co Ltd's total assets of CN¥5.17 Billion consist of 62.4% current assets and 37.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 25.2% |
| Accounts Receivable | CN¥1.02 Billion | 18.3% |
| Inventory | CN¥441.48 Million | 8.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥807.41 Million | 14.5% |
| Goodwill | CN¥6.95 Million | 0.1% |
Asset Composition Trend (2006–2024)
This chart illustrates how Guangdong Zhongsheng Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guangdong Zhongsheng Pharmaceutical Co Ltd's current assets represent 62.4% of total assets in 2024, an increase from 59.6% in 2006.
- Cash Position: Cash and equivalents constituted 25.2% of total assets in 2024, up from 17.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 10.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 18.3% of total assets.
Guangdong Zhongsheng Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Guangdong Zhongsheng Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Guangdong Zhongsheng Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Guangdong Zhongsheng Pharmaceutical Co Ltd generates 0.44x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Guangdong Zhongsheng Pharmaceutical Co Ltd is currently not profitable relative to its asset base.
Guangdong Zhongsheng Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.73 | 7.79 | 3.82 |
| Quick Ratio | 3.31 | 6.64 | 3.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.27 Billion | CN¥ 2.84 Billion | CN¥ 2.31 Billion |
Guangdong Zhongsheng Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guangdong Zhongsheng Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.00 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | -14.0% |
| Total Assets | CN¥5.55 Billion |
| Market Capitalization | $1.49 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Guangdong Zhongsheng Pharmaceutical Co Ltd's assets below their book value (0.27 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Guangdong Zhongsheng Pharmaceutical Co Ltd's assets decreased by 14.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Guangdong Zhongsheng Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual total assets of Guangdong Zhongsheng Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.55 Billion | -14.01% |
| 2023-12-31 | CN¥6.46 Billion | +11.83% |
| 2022-12-31 | CN¥5.78 Billion | +17.82% |
| 2021-12-31 | CN¥4.90 Billion | +2.64% |
| 2020-12-31 | CN¥4.78 Billion | -13.27% |
| 2019-12-31 | CN¥5.51 Billion | +5.00% |
| 2018-12-31 | CN¥5.24 Billion | +7.99% |
| 2017-12-31 | CN¥4.86 Billion | +14.93% |
| 2016-12-31 | CN¥4.23 Billion | +26.74% |
| 2015-12-31 | CN¥3.33 Billion | +44.56% |
| 2014-12-31 | CN¥2.31 Billion | +16.43% |
| 2013-12-31 | CN¥1.98 Billion | +14.04% |
| 2012-12-31 | CN¥1.74 Billion | +10.66% |
| 2011-12-31 | CN¥1.57 Billion | +5.91% |
| 2010-12-31 | CN¥1.48 Billion | +5.60% |
| 2009-12-31 | CN¥1.40 Billion | +345.70% |
| 2008-12-31 | CN¥314.92 Million | +5.77% |
| 2007-12-31 | CN¥297.74 Million | +2.09% |
| 2006-12-31 | CN¥291.65 Million | -- |